Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma.
Twenty patients with metastasis of gastrointestinal malignancies were treated with an anti-colorectal cancer mouse monoclonal antibody 1083-17-1A of the IgG2a class between December 1980 and January 1983. With two exceptions, all patients received a single injection of monoclonal antibody in a dose range of 15-1,000 mg/patient. No untoward immediate or delayed reaction to the initial injection was observed in any of the patients. Mouse immunoglobulin circulated in the patients' blood for 2-50 days, depending on the dose of monoclonal antibody injected, and was detected in tumor tissue within 1 week of its administration. Eight of nine patients who received doses of 366-1,000 mg monoclonal antibody did not develop anti-mouse antibodies, while eight of nine who received less than 200 mg developed anti-mouse immunoglobulin antibody. Three of this heterogeneous group of patients have no detectable disease now--10, 13, and 22 months since immunotherapy.
D000230:Adenocarcinoma / Q000628:therapy*; D000328:Adult; D000368:Aged; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000912:Antibodies, Neoplasm / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000628:therapy*; D006801:Humans; D007116:Immunization, Passive; D007074:Immunoglobulin G / Q000378:metabolism; D008297:Male; D051379:Mice; D008875:Middle Aged
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D007074:Immunoglobulin G